We are live on !
Find out more
APM
Avidity Partners Management Portfolio holdings
AUM
$624M
Turnover
44.83%
1-Year Est. Return
250.2%
This Fund
S&P 500
This Quarter Est. Return
+8.62%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$4.71B
AUM Growth
+$201M
(+4.5%)
Cap. Flow
+$657M
Cap. Flow % of AUM
Cap. Flow %
13.94%
Top 10 Holdings %
Top 10 Hldgs %
37.6%
Holding
120
New
15
Increased
43
Reduced
17
Closed
23
Avg Time Held
Equity + Options
0.6
years
Top 10 Avg Time Held
Equity + Options
0.6
years
Top 20 Avg Time Held
Equity + Options
0.5
years
Avg Time Held Equity only
0.6
years
Top 10 Avg Time Held Equity only
0.6
years
Top 20 Avg Time Held Equity only
0.5
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$135M |
| 2 |
AstraZeneca
AZN
|
+$85.6M |
| 3 |
Baxter International
BAX
|
+$72.7M |
| 4 |
Avantor
AVTR
|
+$60.9M |
| 5 |
UnitedHealth
UNH
|
+$55.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$126M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
+$92.2M |
| 3 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$39.7M |
| 4 |
Exact Sciences
EXAS
|
+$35.2M |
| 5 |
Compass Pathways
CMPS
|
+$34.7M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 99.27% |
| 2 | Financials | 0.5% |
| 3 | Technology | 0.22% |
| 4 | Miscellaneous | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Alnylam Pharmaceuticals
ALNY
$31B
| $62.7M | 1.33% |
370,000
-57,000
| -13% | -$10.6M |
2021 Q1
3 quarters
|
|
|
27
UnitedHealth
UNH
$360B
| $61.8M | 1.31% |
+123,100
| New | +$55.7M |
2021 Q4
0 quarters
|
|
|
28
Vertex Pharmaceuticals
VRTX
$127B
| $61.5M | 1.3% |
280,000
-646,400
| -70% | -$126M |
2020 Q4
4 quarters
|
|
29
IDEAYA Biosciences
IDYA
$3.17B
| $60.4M | 1.28% |
2,553,000
+116,000
| +5% | +$2.69M |
2021 Q1
3 quarters
|
|
30
Ultragenyx Pharmaceutical
RARE
$1.43B
| $58.9M | 1.25% |
700,000
+245,000
| +54% | +$19.9M |
2021 Q3
1 quarter
|
|
31
Arrowhead Research
ARWR
$7.9B
| $58M | 1.23% |
875,000
+201,300
| +30% | +$13.8M |
2021 Q2
2 quarters
|
|
32
Stevanato
STVN
$5.16B
| $57.1M | 1.21% |
2,541,893
| – | – |
2021 Q3
1 quarter
|
|
33
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
| $56.2M | 1.19% |
4,370,000
-87,831
| -2% | -$973K |
2020 Q4
4 quarters
|
|
34
DELISTED
Kezar Life Sciences
KZR
| $54M | 1.14% |
322,820
+296,820
| +1,142% | +$33.5M |
2021 Q3
1 quarter
|
|
35
Adicet Bio
ACET
$42.8M
| $53.1M | 1.13% |
189,625
+38,400
| +25% | +$6.59M |
2021 Q1
3 quarters
|
|
|
RNAM
36
DELISTED
Avidity Biosciences
RNAM
| $43.1M | 0.92% |
1,815,000
+170,000
| +10% | +$4.06M |
2021 Q3
1 quarter
|
|
37
Kymera Therapeutics
KYMR
$8.71B
| $42.5M | 0.9% |
670,000
+155,500
| +30% | +$9.06M |
2021 Q3
1 quarter
|
|
38
Immunocore
IMCR
$1.51B
| $42.1M | 0.89% |
1,230,000
+134,400
| +12% | +$4.87M |
2021 Q1
3 quarters
|
|
39
Caribou Biosciences
CRBU
$50.4M
| $40.4M | 0.86% |
2,674,067
+200,000
| +8% | +$3.89M |
2021 Q3
1 quarter
|
|
40
Insmed
INSM
$21B
| $39.5M | 0.84% |
1,450,000
+158,000
| +12% | +$4.52M |
2021 Q2
2 quarters
|
|
|
OCDX
41
DELISTED
Ortho Clinical Diagnostics Holdings plc Ordinary Shares
OCDX
| $38.3M | 0.81% |
1,790,000
-608,000
| -25% | -$12M |
2021 Q3
1 quarter
|
|
42
Phathom Pharmaceuticals
PHAT
$560M
| $37.3M | 0.79% |
+1,896,000
| New | +$44.6M |
2021 Q4
0 quarters
|
|
43
DELISTED
ESSA Pharma
EPIX
| $34.9M | 0.74% |
2,460,000
+10,000
| +0.4% | +$111K |
2020 Q3
5 quarters
|
|
44
AMN Healthcare
AMN
$1.57B
| $34.3M | 0.73% |
+280,100
| New | +$31.1M |
2021 Q4
0 quarters
|
|
45
Legend Biotech
LEGN
$3.59B
| $33.2M | 0.7% |
711,900
-182,100
| -20% | -$9.24M |
2021 Q2
2 quarters
|
|
46
Alphatec Holdings
ATEC
$1.62B
| $31.7M | 0.67% |
2,773,000
-13,000
| -0.5% | -$153K |
2020 Q4
4 quarters
|
|
|
BLU
47
DELISTED
BELLUS Health Inc.
BLU
| $30.4M | 0.64% |
3,775,000
-1,167,000
| -24% | -$7.74M |
2020 Q4
4 quarters
|
|
48
Vir Biotechnology
VIR
$1.69B
| $29.3M | 0.62% |
700,000
+185,000
| +36% | +$7.25M |
2021 Q2
2 quarters
|
|
49
Axsome Therapeutics
AXSM
$8.23B
| $29.3M | 0.62% |
+775,000
| New | +$28.5M |
2021 Q4
0 quarters
|
|
|
SPNE
50
DELISTED
SeaSpine Holdings Corporation Common Stock
SPNE
| $27.4M | 0.58% |
2,010,000
+67,000
| +3% | +$962K |
2021 Q2
2 quarters
|
|
Similar funds
RIP
PWS
LWP
BVC
Avidity Partners Management's Q4 2021 Portfolio in Review
As of Q4 2021, Avidity Partners Management held 120 positions worth $4.71B, up 4.5% from $4.51B the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Avidity Partners Management deployed $657M of net new capital in Q4 2021, opening 15 new positions and adding to 43 existing holdings. Its largest new stake was Elevance Health: 321,000 shares worth $149M.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 85% a quarter earlier, followed by Financials and Technology.
On the sell side, the largest reduction was Vertex Pharmaceuticals, an estimated $126M trimmed.
- Avidity Partners Management's largest Q4 2021 buy was Elevance Health: 321,000 shares worth $149M.
- Avidity Partners Management added most to AstraZeneca in Q4 2021, an estimated $85.6M increase.
- Avidity Partners Management's biggest Q4 2021 reduction was Vertex Pharmaceuticals, cutting an estimated $126M.
- Avidity Partners Management fully exited Regeneron Pharmaceuticals in Q4 2021, selling an estimated $92.2M.
- Avidity Partners Management's ten largest holdings make up 38% of its $4.71B portfolio in Q4 2021.
- Avidity Partners Management opened 15 new positions and closed 23 in Q4 2021.
- Avidity Partners Management's portfolio value rose 4.5% quarter-over-quarter to $4.71B.
Based on Avidity Partners Management's 13F filing for Q4 2021, filed 14 Feb 2022.